Vorapaxar Sulfate

硫酸沃拉帕沙

Report date: 2024/06/27 20:00:09
NMEFirst In Class

Base Information

Drug NameVorapaxar Sulfate
Drug Alias NameVorapaxarum沃雷帕萨沃拉帕沙ZontivitySCH-530348 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProtease-activated receptor-1 antagonists
TargetsProtease-activated receptor-1
Therapy Area/IndicationsIschemiaThrombosisPeripheral Arterial Disease +[13] 
Global Approved IndicationsThrombosisPeripheral Arterial DiseaseMyocardial Infarction +[4] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2014/05/08
Country/TerritoryUnited StatesAustraliaEU
CombinationsNo
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKey Therapeutics LLCKirby InstituteMerck Sharp & Dohme Ltd +[5] 
Active IndicationsN/A
Inactive IndicationsIschemiaThrombosisPeripheral Arterial Disease +[13] 

Other Information

ATC CodeB01AC26
Related LinksWikipediaDrugBankKEGG